DocWire News Editors

DocwireNews

The administration of omega-3 carboxylic acid (CA) at a high dose did not reduce the incidence of major adverse cardiovascular events compared with placebo, according to the results of the STRENGTH trial. This lack of benefit occurred despite a nearly 300% increase in plasma EPA levels.Results were presented by A. Michael Lincoff, MD, vice chairman for Research of the Department of Cardiovascular Medicine and an interventional cardiologist in the Heart, Vascular &amp; Thoracic Institute at the Cleveland Clinic, as part of a news briefing at the American Heart Association Scientific Sessions 2020.The cardiovascular benefits of administration of omega-3 fatty acids remains incompletely defined, Dr. Lincoff explained. Omega-3 CA does not require pancreatic lipase for absorption and, thus, has enhanced bioavailability to achieve higher and more reliable blood levels.To test omega-3 CA, STRENGTH enrolled patients were statin-treated and had or were at high risk for cardiovascular disease with triglycerides ranging from 180 mg/dL to 500 mg/dL and HDL less than 42 mg/dL for men and 47 mg/dL for women. The primary endpoint was cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina.In the trial, 13,078 patients from 676 sites in 22 countries were randomly assigned to omega-3 CA (EPA + DHA) 4 g daily or identical corn-oil placebo. Median follow-up was 42.0 months. Patients were randomized from October 2014 to June 2017. In January 2020, the Data Monitoring Committee recommended stopping the trial for futility after reviewing 1,384 primary endpoints.With a median follow-up of about three years, 1,580 patients had experienced at least one cardiac event.For patients assigned to omega-3 CA triglyceride levels were reduced by 19% and hsCRP was reduced by 20% for patients. There were little differences in LDL or HDL between baseline and follow-up with administration of omega-3.Plasma and red blood cell levels of EPA were increased between 268.8% and 298.6%, respectively. There were more modest increases in DHA for plasma and red blood cells (39.7% and 23.9%). Despite the biochemical effects, there was no difference in the primary outcome with treatment with omega-3 CA and placebo, with superimposable survival curves.The major adverse effect of concern was atrial fibrillation, which was increased by about 70% with omega-3 CA (HR=1.69; 95% CI, 1.29 to 2.21).&ldquo;These findings, in the context of the increased risk of atrial fibrillation in this and other trials of omega-3 fatty acids, cast a question regarding whether or not there is a net benefit or harm with any omega-3 fatty acid preparation,&rdquo; Dr. Lincoff concluded.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

STRENGTH: Fish Oil Medication Did Not Reduce Risk for CV Events

AHA Scientific Sessions 2020

The administration of omega-3 carboxylic acid (CA) at a high dose did not reduce the incidence of major adverse cardiovascular events compared with placebo, according to the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe